Inotek Pharmaceuticals Corporation Announces Study Results Demonstrating Neuroprotective Properties Of Trabodenoson, Its Lead Drug Candidate For Glaucoma
5/30/2014 9:27:52 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Inc., a leader in the development of innovative products for the treatment of glaucoma, today announced the results from a preclinical study demonstrating the ability of trabodenoson, an adenosine A1 mimetic in development for glaucoma, to protect against the loss of retinal ganglion cells in an acute high-ocular-pressure animal model of glaucoma. Retinal ganglion cells are the part of the nervous system responsible for relaying the visual image from the eye to the brain, and their death is what causes the irreversible vision loss associated with glaucoma. The results of this study were presented this month at the 2014 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
Help employers find you! Check out all the jobs and post your resume.
comments powered by